Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product, By Indication, By Region, And Segment Forecasts, 2025

The global cell and gene therapy CDMO market size was valued at USD 4.31 billion in 2024 and is projected to reach USD 27.12 billion by 2033, growing at a CAGR of 23.03% from 2025 to 2033. The industry is driven by the expanding portfolio of cell and gene therapy products, increased researcher attention on rare diseases, and substantial investments from both public and private sectors in research and development.

The rising demand for outsourced services related to cell and gene therapies, the increasing prevalence of chronic ailments such as cancer, a surge in mergers & acquisitions activities, and ongoing technological innovations throughout the cell and gene therapy development process are also fueling the growth. The market is primarily driven by the increased R&D funding and investments in cell and gene therapeutics (CGT) by the biotechnology and pharmaceutical industries. Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

Furthermore, an increased clinical pipeline and persistent reliance on outsourcing due to the specialized expertise and infrastructure required for production are also factors which is driving market growth. According to the data published by clinicaltrials.org there are currently over 2,000 ongoing clinical trials in cell and gene therapies that are progressing through development stages, and each transition from early to late phase amplifies the demand for viral vectors, plasmids, and clinical-grade cell processing. FDA approvals of novel treatments such as Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy in 2023-24, alongside EMA's approval of Roctavian for hemophilia A, highlight the growing momentum of advanced therapies entering the commercial stage. Most small and mid-sized biotech firms pioneering these innovations lack large-scale GMP facilities, making partnerships with CDMOs essential to reach patients. To meet this surge, leading players like Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher have invested heavily in expanding viral vector and cell therapy capacity, indicating strong confidence in sustained outsourcing demand. Together, these drivers position the market for sustained high growth as approvals accelerate, pipelines deepen, and manufacturing needs outpace in-house capabilities.

Global Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell and gene therapy CDMO market report based on phase, product, indication, and region.

Phase Outlook (Revenue, USD Million, 2021 - 2033)
Pre-clinical
Clinical
Product Outlook (Revenue, USD Million, 2021 - 2033)
Gene Therapy
- Ex-vivo
- In-vivo
Gene-Modified Cell Therapy
- CAR T-cell therapies
- CAR-NK cell therapy
- TCR-T cell therapy
- Others
Cell Therapy
Indication Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Infectious Diseases
Neurological disorders
Rare Diseases
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar

Product Code: GVR-4-68040-167-4

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
3.2. Cell And Gene Therapy CDMO Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Cell And Gene Therapy CDMO Market: Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis

Chapter 4. Cell And Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Cell And Gene Therapy CDMO Market Phase Movement Analysis
4.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
4.4. Pre-clinical
- 4.4.1. Pre-clinical Market Estimates and Forecasts, 2021 - 2033 (USD million)
4.5. Clinical
- 4.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Cell And Gene Therapy CDMO Market Product Type Movement Analysis
5.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
5.4. Gene Therapy
- 5.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.2. Ex-vivo
  - 5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4.3. In-vivo
  - 5.4.3.1. In-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Gene-Modified Cell Therapy
- 5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5.2. CAR T-cell therapies
  - 5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5.3. CAR-NK cell therapy
  - 5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5.4. TCR-T cell therapy
  - 5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5.5. Other
  - 5.5.5.1. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Cell Therapy
- 5.6.1. Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Cell And Gene Therapy CDMO Market Indication Movement Analysis
6.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Oncology
- 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Infectious Diseases
- 6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Neurological disorders
- 6.6.1. Neurological disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Rare Diseases
- 6.7.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
- 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cell And Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use

7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Competitive Scenario
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Competitive Scenario
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Competitive Scenario
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Competitive Scenario
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Competitive Scenario
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Competitive Scenario
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Competitive Scenario
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Competitive Scenario
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Competitive Scenario
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Competitive Scenario
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Competitive Scenario
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Competitive Scenario
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Competitive Scenario
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Competitive Scenario
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Competitive Scenario
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Competitive Scenario
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Competitive Scenario
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Competitive Scenario
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Competitive Scenario
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. MEA
- 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Competitive Scenario
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Competitive Scenario
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Competitive Scenario
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Competitive Scenario
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.6. Oman
  - 7.8.6.1. Key Country Dynamics
  - 7.8.6.2. Competitive Scenario
  - 7.8.6.3. Regulatory Framework
  - 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.7. Qatar
  - 7.8.7.1. Key Country Dynamics
  - 7.8.7.2. Competitive Scenario
  - 7.8.7.3. Regulatory Framework
  - 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Cell And Gene Therapy CDMO Market Share Analysis, 2024
8.3. Company Profiles
- 8.3.1. Lonza
  - 8.3.1.1. Company overview
  - 8.3.1.2. Financial performance
  - 8.3.1.3. Product benchmarking
  - 8.3.1.4. Strategic initiatives
- 8.3.2. Catalent, Inc
  - 8.3.2.1. Company overview
  - 8.3.2.2. Financial performance
  - 8.3.2.3. Product benchmarking
  - 8.3.2.4. Strategic initiatives
- 8.3.3. Cytiva
  - 8.3.3.1. Company overview
  - 8.3.3.2. Financial performance
  - 8.3.3.3. Product benchmarking
  - 8.3.3.4. Strategic initiatives
- 8.3.4. Samsung Biologics
  - 8.3.4.1. Company overview
  - 8.3.4.2. Financial performance
  - 8.3.4.3. Product benchmarking
  - 8.3.4.4. Strategic initiatives
- 8.3.5. Thermo Fisher Scientific Inc.
  - 8.3.5.1. Company overview
  - 8.3.5.2. Financial performance
  - 8.3.5.3. Product benchmarking
  - 8.3.5.4. Strategic initiatives
- 8.3.6. Novartis AG
  - 8.3.6.1. Company overview
  - 8.3.6.2. Financial performance
  - 8.3.6.3. Product benchmarking
  - 8.3.6.4. Strategic initiatives
- 8.3.7. WuXi AppTec
  - 8.3.7.1. Company overview
  - 8.3.7.2. Financial performance
  - 8.3.7.3. Product benchmarking
  - 8.3.7.4. Strategic initiatives
- 8.3.8. AGC Biologics
  - 8.3.8.1. Company overview
  - 8.3.8.2. Financial performance
  - 8.3.8.3. Product benchmarking
  - 8.3.8.4. Strategic initiatives
- 8.3.9. OmniaBio
  - 8.3.9.1. Company overview
  - 8.3.9.2. Financial performance
  - 8.3.9.3. Product benchmarking
  - 8.3.9.4. Strategic initiatives
- 8.3.10. Charles River Laboratories
  - 8.3.10.1. Company overview
  - 8.3.10.2. Financial performance
  - 8.3.10.3. Product benchmarking
  - 8.3.10.4. Strategic initiatives
- 8.3.11. Rentschler Biopharma SE
  - 8.3.11.1. Company overview
  - 8.3.11.2. Financial performance
  - 8.3.11.3. Product benchmarking
  - 8.3.11.4. Strategic initiatives

Product Code: GVR-4-68040-167-4

List of Tables

Table 1 List of abbreviation
Table 2 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
Table 3 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 4 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 5 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 6 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 7 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 8 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 9 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 10 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 11 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 12 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 13 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 14 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 15 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
Table 16 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 17 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 18 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 19 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 20 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 21 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 22 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 23 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 24 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 25 France Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 26 France Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 27 France Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 28 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 29 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 30 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 31 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 32 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 33 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 34 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 35 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 36 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 37 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 38 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 39 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 40 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 41 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 42 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 43 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
Table 44 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 45 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 46 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 47 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 48 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 49 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 50 China Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 51 China Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 52 China Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 53 India Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 54 India Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 55 India Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 56 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 57 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 58 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 59 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 60 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 61 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 62 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 63 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 64 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 65 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
Table 66 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 67 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 68 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 69 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 70 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 71 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 72 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 73 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 74 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 75 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
Table 76 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 77 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 78 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 79 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 80 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 81 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 82 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 83 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 84 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 85 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 86 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 87 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 88 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 89 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 90 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 91 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 92 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 93 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
Table 94 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
Table 95 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
Table 96 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Cell And Gene Therapy CDMO Market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Segment snapshot
Fig. 15 Competitive landscape snapshot
Fig. 16 Parent market outlook, 2024 (USD Million)
Fig. 17 Ancillary market outlook, 2024 (USD Million)
Fig. 18 Cell And Gene Therapy CDMO Market dynamics
Fig. 19 Total R&D drug pipeline size, 2021 - 2024
Fig. 20 Total drug pipeline by development phase, 2024
Fig. 21 Porter's five forces analysis
Fig. 22 PESTEL analysis
Fig. 23 Cell And Gene Therapy CDMO Market Phase outlook: Segment dashboard
Fig. 24 Cell And Gene Therapy CDMO Market, by Phase segment: Market share, 2025 & 2033
Fig. 25 Pre-clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 27 Cell And Gene Therapy CDMO Market Product Type outlook: Segment dashboard
Fig. 28 Cell And Gene Therapy CDMO Market, by Product Type segment: Market share, 2025 & 2033
Fig. 29 Gene Therapy Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Ex-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 In-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 33 CAR T-cell therapies market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 34 CAR-NK cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 35 TCR-T cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 36 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 37 Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 38 Cell And Gene Therapy CDMO Market Indication outlook: Segment dashboard
Fig. 39 Cell And Gene Therapy CDMO Market, by Indication segment: Market share, 2025 & 2033
Fig. 40 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 41 Infectious Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 42 Neurological disorders market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 43 Rare Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 45 Regional market: Key takeaways
Fig. 46 Regional marketplace: Key takeaways
Fig. 47 North America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 54 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 UK Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 France Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 65 Key country dynamics
Fig. 66 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 71 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 72 Key country dynamics
Fig. 73 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 74 Key country dynamics
Fig. 75 China Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 India Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 78 Key country dynamics
Fig. 79 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 80 Key country dynamics
Fig. 81 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 84 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 85 Key country dynamics
Fig. 86 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 89 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 102 Market participant categorization
Fig. 103 Heat map analysis

Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Cell And Gene Therapy CDMO Market Summary

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope

Chapter 4. Cell And Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

Chapter 5. Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis

Chapter 6. Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

Chapter 7. Cell And Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use

Chapter 8. Competitive Landscape

List of Tables

List of Figures